Dhipatimendi rePasi Pose

Musi wa25 Kubvumbi, 2025, InnoCare Pharma yakazivisa kuti mushonga wayo mutsva wepan-TRK inhibitor zurletrectinib (ICP-723) wapihwa mukana wekutarisa neCenter for Drug Evaluation (CDE) yeChina National Medical Products Administration (NMPA), iyo yakabvuma New Drug Application (NDA) ye z...Verenga zvakawanda»

Musi wa25 Kubvumbi, 2025, Innovent Biologics yakazivisa kuti National Medical Products Administration (NMPA) yeChina yakabvumidza New Drug Application (NDA) ye limertinib senzira yekutanga yekurapa varwere vakuru vane chirwere chekenza yemapapu chisiri chemasero madiki (NSCLC) chakakwira kana kuti chakapararira munharaunda...Verenga zvakawanda»

Musi wa23 Kubvumbi, mushonga weAkeso wepenpulimab wakawana mvumo kubva kuFood and Drug Administration pamwe chete ne cisplatin kana carboplatin uye gemcitabine yekurapa vanhu vakuru vane chirwere chekenza chemudumbu chisingarapiki kana kuti chinokanganisa ganda (NPC). FDA yakabvumidzawo penpulimab-kcqx sechivi...Verenga zvakawanda»

Musi wa16 Kurume, 2025, Akeso yakazivisa kuti mushonga wayo mutsva wekudzivirira chirwere chePD-1 monoclonal, penpulimab, wakabvumidzwa zviri pamutemo neNational Medical Products Administration (NMPA) wekurapa gomarara remumhino rinodzoka kana kuti rakapararira mumuviri (NPC) pamwe chete ...Verenga zvakawanda»

Musi wa24 Kubvumbi, 2025, GenFleet Therapeutics yakazivisa kuti US Food and Drug Administration (FDA) yakabvumidza kushandiswa kwemushonga mutsva (IND) weGFH375/VS-7375, mushonga unodzivisa KRAS G12D (ON/OFF) nemuromo, wekuyedzwa kwekiriniki kurapa varwere vane bundu rakasimba vane KRAS G12D mutation. Chidzidzo ichi...Verenga zvakawanda»

Musi wa17 Kubvumbi, 2025, Hansoh Pharmaceutical yakazivisa kuti mushonga weB7-H3-targeted antibody-drug conjugate (ADC) HS-20093 weBoka wakazvigadzira wega wekubaiwa jekiseni wawana mvumo yekuverengerwa semushonga weBreakthrough-Therapy-Designated neNational Medical Products Administration (NMPA) yeChina, ...Verenga zvakawanda»

Musi wa15 Kubvumbi, 2025, InnoCare Pharma yakazivisa kuti Center for Drug Evaluation (CDE) yeChina National Medical Products Administration (NMPA) yakagamuchira New Drug Application (NDA) yechizvarwa chayo chitsva chepan-TRK inhibitor zurletrectinib (ICP-723) yekurapa vanhu vakuru nevechidiki...Verenga zvakawanda»

Munguva pfupi yapfuura, GenFleet yakazivisa data razvino rechikamu chechipiri chekudzidza kweKROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) pamwe chete necetuximab yekurapa kenza yemapapu isiri diki (NSCLC) yekutanga, muchidimbu chakapedzisira kuitika pamusangano mudiki weEuropean Lung Cancer Conf wa2025...Verenga zvakawanda»

PLB1004, yakagadzirwa neBeijing Avistone Biotechnology Co., Ltd., mushonga wakachengeteka, unosarudza zvakanyanya, uye unoshanda zvakanaka we tyrosine kinase inhibitor (EGFR-TKI) unoshandiswa kurapa kenza yemapapu isiri diki (NSCLC). Musi wa9 Kubvumbi, 2025, National Medical Products Admi...Verenga zvakawanda»

Musi wa13 Kurume, 2025, magazini yepamusoro yepasi rose yeNature Medicine yakaburitsa bvunzo yeMediLink yeB7-H3 inotarisa antibody drug conjugate (ADC) YL201 Phase 1/1b. Muedzo uyu waisanganisira chikamu chekuwedzerwa kwedosi (chikamu 1) uye chikamu chekuwedzerwa kwedosi (chikamu 1b). Varwere vanosvika 312 vakanyoreswa pakati pe...Verenga zvakawanda»

Musi wa21 Kurume, 2025, Immunofoco yakazivisa kuti EpCAM-targeting autologous CAR-T cell therapy yayo yakazvimiririra, IMC001, yakapihwa mvumo neCenter for Drug Evaluation (CDE) pasi peNational Medical Products Administration (NMPA) muChina kuti iite chirongwa chayo chechipiri cheInvestigational New Drug...Verenga zvakawanda»

Musi wa31 Kurume, 2025, Innovent Biologics yakazivisa kuti Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yeChina yakapa Breakthrough Therapy Designation (BTD) yeIBI363, protein yekutanga mukirasi yePD-1/IL-2α-bias bispecific antibody fusion, senzira yekurapa chete ye...Verenga zvakawanda»